A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced PANCreatic Ductal Adenocarcinoma who are candidates for surgical resection
Study of Zimberelimab in Patients with Advanced Pancreatic Cancer who are Eligible for Surgery
Sponsor: Arcus Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU4206
U.S. Govt. ID: NCT06048484
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main goal of this study is to find out if treatment with zimberelimab and stereotactic body radiation therapy alone or in combination with quemliclustat, with or without etrumadenant, given before surgery is safe and if it can further increase the immune response against the tumor.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Have you been diagnosed with pancreatic cancer? Yes No
Are you comfortable receiving the study drug through a vein in your arm? Yes No
Are you willing to undergo surgery? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE